🧪FDA Classifies Zika Virus Serological Reagents to Class II
Medical Devices; Immunology and Microbiology Devices; Classification of the Zika Virus Serological Reagents
Summary
The Food and Drug Administration (FDA, Agency, or we) is classifying the Zika virus serological reagents into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the Zika virus serological reagents' classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices in part by reducing regulatory burdens.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$$ - High
The regulation details the classification of Zika virus serological reagents into class II, impacting businesses that develop or market medical devices. Compliance with special controls reduces regulatory burdens, facilitating faster market access for innovative products. This could lead to increased opportunities for companies in the diagnostics market.